Hemophilia A gene therapy: AAV-mediated delivery of an enhanced F8 cassette to the liver produces supraphysiological levels of human FVIII in vivo
|
|
- Aldous Nicholson
- 5 years ago
- Views:
Transcription
1 Hemophilia A gene therapy: AAV-mediated delivery of an enhanced F8 cassette to the liver produces supraphysiological levels of human FVIII in vivo Brigit E. RILEY Director Discovery and Translational Research Sangamo BioSciences USA 1
2 Disclosures for: Brigit E. RILEY In compliance with the PIM* policy, WFH requires the following disclosures be made at each presentation CONFLICT RESEARCH SUPPORT DIRECTOR, OFFICER, EMPLOYEE DISCLOSURE IF CONFLICT OF INTEREST EXISTS Sangamo BioSciences DIRECTOR SHAREHOLDER HONORARIA ADVISORY COMMITTEE CONSULTANT * Postgraduate Institute for Medicine 2
3 I N T R O S L I D E / A G E N D A C L I C K T O E D I T M A S T E R T I T L E S T Y L E Background Hemophilia A and AAV Gene Therapy Overview of AAV Factor 8 cdna Approach to Optimizing AAV Factor 8 cdna Evaluating the Optimized AAV Factor 8 cdna in vitro: HepG2 Cells in vivo: Wild Type and Hemophilia A mouse models in vivo: Non-Human Primates (NHPs) Summary and Next Steps 3
4 I N T R O S L I D E / A G E N D A C L I C K T O E D I T M A S T E R T I T L E S T Y L E Background Hemophilia A and AAV Gene Therapy Overview of AAV Factor 8 cdna Approach to Optimizing AAV Factor 8 cdna Evaluating the Optimized AAV Factor 8 cdna in vitro: HepG2 Cells in vivo: Wild Type and Hemophilia A mouse models in vivo: Non-Human Primates (NHPs) Summary and Next Steps 4
5 H E M O P H I L I A A A N I D E A L D I S E A S E F O R L I V E R - D I R E C T E D G E N E T H E R A P Y Modest increases in Factor VIII levels (>1% of normal) have a positive impact on patient lives Adeno-associated virus (AAV) vectors have shown efficacy in preclinical and clinical studies; stable Factor IX (FIX) expression ~ five years in the clinic Lag in the clinic of AAV human Factor 8 (hf8) gene therapy poor vector yields at clinical scale and dose required to achieve therapeutic FVIII levels We optimized an AAV hf8 cdna vector cassette to improve both vector yields and liver-specific hfviii expression Administration of the enhanced AAV hf8 cdna vector in vivo resulted in 2-8X normal circulating hfviii levels * Higher circulating hfviii levels will enable lower dose in the clinic 5
6 H E M O P H I L I A A L I V E R - D I R E C T E D A AV F 8 C D N A G E N E T H E R A P Y 6
7 H E M O P H I L I A A L I V E R - D I R E C T E D A AV F 8 C D N A G E N E T H E R A P Y Transgene packaged into AAV vectors Transgene packaged into AAV vectors Therapeutic delivered by a single infusion AAV vectors P TG transgene P } liver- specific promoter TG } therapeutic gene (F8) 7
8 H E M O P H I L I A A L I V E R - D I R E C T E D A AV F 8 C D N A G E N E T H E R A P Y Transgene packaged into AAV vectors Transgene packaged into AAV vectors AAV is delivered by a single infusion Therapeutic delivered by a single infusion AAV vectors P TG transgene P } liver- specific promoter TG } therapeutic gene (F8) 8
9 H E M O P H I L I A A L I V E R - D I R E C T E D A AV F 8 C D N A G E N E T H E R A P Y Transgene packaged into AAV vectors Transgene packaged into AAV vectors AAV is delivered by a single infusion Therapeutic delivered by a single infusion AAV traffics to liver to deliver transgene into nucleus of liver cells AAV vectors P TG transgene Liver Cell DNA Promoter P } liver- specific promoter TG } therapeutic gene (F8) Therapeutic Gene (hf8) Nucleus Liver Cell Liver produces and secretes therapeutic hfviii protein 9
10 H E M O P H I L I A A L I V E R - D I R E C T E D A AV F 8 C D N A G E N E T H E R A P Y Transgene packaged into AAV vectors Transgene packaged into AAV vectors AAV is delivered by a single infusion Therapeutic delivered by a single infusion AAV traffics to liver to deliver transgene into nucleus of liver cells AAV vectors P TG transgene Liver Cell DNA Promoter P } liver- specific promoter TG } therapeutic gene (F8) Therapeutic Gene (hf8) Nucleus Liver Cell Liver produces and secretes therapeutic hfviii protein Transgene is expressed from the liver, but remains separate from the cell s DNA 10
11 H E M O P H I L I A A L I V E R - D I R E C T E D A AV F 8 C D N A G E N E T H E R A P Y Transgene packaged into AAV vectors Transgene packaged into AAV vectors AAV is delivered by a single infusion Therapeutic delivered by a single infusion AAV traffics to liver to deliver transgene into nucleus of liver cells AAV vectors P TG transgene Liver Cell DNA Promoter P } liver- specific promoter TG } therapeutic gene (F8) Therapeutic Gene (hf8) Nucleus Liver Cell Liver produces and secretes therapeutic hfviii protein Transgene is expressed from the liver, but remains separate from the cell s DNA 11
12 W I L D T Y P E A AV Single-stranded DNA virus which requires a helper virus for replication No pathology associated with AAV infection Tissue selectivity is determined by capsid composition Tissue Selectivity of AAV Serotypes AAV1 AAV2 AAV3 AAV4 AAV5 AAV6 AAV7 AAV8 AAV9 Liver, Heart, Skeletal muscle Liver, Heart, and muscle Heart, Liver Heart, Lung, Liver Liver Liver, Heart, Skeletal muscle Liver, Skeletal muscle Liver, Heart, Brain, Muscle Liver, Heart, Brain, Lung, Skeletal muscle Vance et al, DOI: /
13 R E C O M B I N A N T A AV Recombinant AAV (raav) has been used extensively for nearly 20 years as a gene therapy vector in preclinical and clinical studies Efficient transduction and long term, stable transgene expression in non-dividing tissues: - Liver, brain and muscle Replication deficient High degree of stability which allows for rigorous methods of vector purification AAV vectors carrying capacity is small (~4.7 kb of DNA) 13
14 G E N E R AT I O N O F R E C O M B I N A N T A AV Wild-Type AAV ITR Recombinant AAV Contains the transgene in place of wild type genes ITR wild type genes Transgene of Interest ITR Replace wild type genes ITR Manufacturing raav Helper plasmid is supplied in trans, together with the transgene to a packaging cell line Helper plasmid ITR ITR Transgene of interest + Highly purified raav cell line Harvest crude raav extract Purify raav - Density gradient - Column purification Within Cell Capsid Assembly Virus Packaging 14
15 I N T R O S L I D E / A G E N D A C L I C K T O E D I T M A S T E R T I T L E S T Y L E Background Hemophilia A and AAV Gene Therapy Overview of AAV Factor 8 cdna Approach to Optimizing AAV Factor 8 cdna Evaluating the Optimized AAV Factor 8 cdna in vitro: HepG2 Cells in vivo: Wild Type and Hemophilia A mouse models in vivo: Non-Human Primates (NHPs) Summary and Next Steps 15
16 W H AT I S O P T I M A L F O R A AV H F 8 C D N A? hf8 is not an ideal gene for AAV: Constrained by hf8 gene size Optimal AAV transgene size is ~4.7 kb; full length hf8 is ~7 kb AAV dose required to achieve therapeutic hfviii levels Low efficiency of transcription/translation Low manufacturing yields of AAV hf8 Clinical scale manufacturing feasibility is limiting Optimal AAV hf8 cdna requires: Shorter coding sequence for hf8 Potential solution is the use of an optimized B-domain deleted sequence (BDD) An optimized robust liver-specific promoter module to drive hf8 expression Improved virus yields 16
17 I N T R O S L I D E / A G E N D A C L I C K T O E D I T M A S T E R T I T L E S T Y L E Background Hemophilia A and AAV Gene Therapy Overview of AAV Factor 8 cdna Approach to Optimizing AAV Factor 8 cdna Evaluating the Optimized AAV Factor 8 cdna in vitro: HepG2 Cells in vivo: Wild Type and Hemophilia A mouse models in vivo: Non-Human Primates (NHPs) Summary and Next Steps 17
18 O P T I M I Z AT I O N O F A AV H F 8 C D N A R E Q U I R E D M U LT I - FA C T O R I A L M O D I F I C AT I O N S Liver Promoter Human Factor 8 B-Domain Deleted (BDD) polya ITR ITR Promoter module modifications Assembled different permutations of liver-specific promoter elements Identified regions of the promoter module that could be improved upon For other elements a systematic mutational design approach was used Transgene modifications Optimized the F8 cassette Other modifications Identified minimal synthetic polya Removed un-necessary nucleic acids Reduced size Optimized sequences outside transgene hfviii protein has the same amino acid sequence as biologics currently in clinic 18
19 I T E R AT I V E P R O C E S S T O I D E N T I F Y A N I M P R O V E D A AV H F 8 C D N A C A S S E T T E Promoter module modifications Virus Yields In Vitro secreted hfviii levels (mrna/protein) and activity Other modifications Transgene modifications In Vivo circulating hfviii levels (mrna/protein) 19
20 Y ie ld (v g ) M O D I F I C AT I O N S I M P R O V E V I R U S Y I E L D Stage 1 Stage 2 Stage 3 Stage Iterative Process to Improve Cassette 20
21 Y ie ld (v g ) M O D I F I C AT I O N S I M P R O V E V I R U S Y I E L D Stage 1 Stage 2 Stage 3 Stage Iterative Process to Improve Cassette 21
22 Y ie ld (v g ) M O D I F I C AT I O N S I M P R O V E V I R U S Y I E L D Stage 1 Stage 2 Stage 3 Stage Iterative Process to Improve Cassette 22
23 Y ie ld (v g ) M O D I F I C AT I O N S I M P R O V E V I R U S Y I E L D Stage 1 Stage 2 Stage 3 Stage fold improvement at the cell factory scale Iterative Process to Improve Cassette At clinical scale; greater than 5-fold improvement in vector yields 23
24 I N T R O S L I D E / A G E N D A C L I C K T O E D I T M A S T E R T I T L E S T Y L E Background Hemophilia A and AAV Gene Therapy Overview of AAV Factor 8 cdna Approach to Optimizing AAV Factor 8 cdna Evaluating the Optimized AAV Factor 8 cdna in vitro: HepG2 Cells in vivo: Wild Type and Hemophilia A mouse models in vivo: Non-Human Primates (NHPs) Summary and Next Steps 24
25 S E V E R A L M E T H O D S U S E D T O A S S E S S H F V I I I L E V E L S A N D A C T I V I T Y Enzyme-Linked Immunosorbent Assay (ELISA) hfviii magnet Clotting Assay Add Ca 2+ Generation of Factor Xa and thrombin yielding clot formation Activator + phospholipids hfviii FVIII deficient plasma magnet Factor X Chromogenic substrate Chromogenic Assay Factor IXa, Ca 2+, Phospholipid hfviii Factor Xa Factor Xa Chromophore 405 nm Clotting times ACTIVITY Not specific for human FVIII LEVELS Specific for human FVIII ACTIVITY Not specific for human FVIII 25
26 I N V I T R O : H E P G 2 C E L L S E X P E R I M E N TA L D E S I G N AAV2 ITR Liver-specific promoter module hfviii BDD PolyA AAV2 ITR Optimized raav hf8 cdna cassette packaged into AAV2/6 Test article addition Endpoints ELISA for hfviii levels days Clotting assay for hfviii activity Supernatant collection schedule Chromogenic assay for hfviii activity 26
27 h F V III A c tiv ity (U /m L ) h F V III (P e r c e n t N o rm a l) I N V I T R O : H E P G 2 C E L L S G O O D C O R R E L AT I O N B E T W E E N H F V I I I A C T I V I T Y / L E V E L S E L IS A C h r o m o g e n ic A s s a y C lo ttin g A s s a y D o s e Values will be reported as hfviii (Percent Normal) for ELISA, Chromogenic or Clotting where 1 U/mL = 100% Normal 4.8E6 / 2.4E6 / 1.2E6 / 0.6E6 MOI 27
28 I N T R O S L I D E / A G E N D A C L I C K T O E D I T M A S T E R T I T L E S T Y L E Background Hemophilia A and AAV Gene Therapy Overview of AAV Factor 8 cdna Approach to Optimizing AAV Factor 8 cdna Evaluating the Optimized AAV Factor 8 cdna in vitro: HepG2 Cells in vivo: Wild Type and Hemophilia A mouse models in vivo: Non-Human Primates (NHPs) Summary and Next Steps 28
29 I N V I V O : W I L D T Y P E M O U S E D ATA E X P E R I M E N TA L D E S I G N AAV2 ITR Liver-specific promoter module hfviii BDD PolyA AAV2 ITR IV injection of test article Optimized raav hf8 cdna cassette packaged into AAV2/ days Plasma collection schedule Dose 7.2E+12 vg/kg Endpoints ELISA for hfviii levels hf8 mrna tissue biodistribution Immunosuppression regimen of cyclophosphamide (50 mg/kg) 29
30 I N V I V O : W I L D T Y P E M O U S E D ATA S U P R A P H Y S I O L O G I C A L L E V E L S h F V III (P e r c e n t N o rm a l) % hfviii Levels F o rm u la tio n A A V h F 8 c D N A Levels were determined by ELISA 30
31 I N V I V O : W I L D T Y P E M O U S E D ATA H F 8 E X P R E S S I O N I S R E S T R I C T E D T O L I V E R N o rm a liz e d h F V III m R N A V a lu e s 8 hf8 mrna L iv e r B r a in K id n e y T e s te s H e a r t S p le e n L u n g Represents two independent mouse studies 31
32 I N V I V O : H E M O P H I L I A A M O U S E D ATA E X P E R I M E N TA L D E S I G N AAV2 ITR Liver-specific promoter module hfviii BDD PolyA AAV2 ITR Optimized raav hf8 cdna cassette packaged into AAV2/6 IV injection of test article Dose 7.2E+12 vg/kg days 3 months Endpoint Chromogenic assay for hfviii activity Tail vein transection (TVT) for hemostasis Plasma collection schedule 32
33 I N V I V O : H E M O P H I L I A A M O U S E D ATA O V E R V I E W O F H E M O P H I L I A A R C M I C E Hemophilia A R593C mice are tolerized to hfviii because they contain a hf8-r593c transgene under control of a murine albumin promoter hfviii-r593c is frequently observed in Hemophilia A patients, and in mice produces no detectable hfviii protein - Thought to be rapidly degraded in mice, with peptide fragments presented to the immune system Mice also contain a knockout of the mouse F8 gene and are deficient for endogenous mouse FVIII protein Studies were conducted in collaboration with Dr. David Lillicrap at Queen s University 33
34 I N V I V O : H E M O P H I L I A A M O U S E D ATA S U P R A P H Y S I O L O G I C A L L E V E L S h F V III (P e r c e n t N o rm a l) h F V III (P e r c e n t N o rm a l) hfviii Activity Day 14 Day % % F o rm u la tio n A A V h F 8 c D N A 0 F o rm u la tio n A A V h F 8 c D N A Activity determined by Chromogenic Activity Assay 34
35 I N V I V O : H E M O P H I L I A A M O U S E D ATA R E D U C E D B L E E D T I M E I N T R E AT E D M I C E T o ta l B le e d in g T im e (m in ) Tail Vein Transection (TVT) p < Normal bleeding time F o rm u la tio n A A V h F 8 c D N A TVT method based on Johansen et al., Haemophilia, 1-7,
36 I N T R O S L I D E / A G E N D A C L I C K T O E D I T M A S T E R T I T L E S T Y L E Background Hemophilia A and AAV Gene Therapy Overview of AAV Factor 8 cdna Approach to Optimizing AAV Factor 8 cdna Evaluating the Optimized AAV Factor 8 cdna in vitro: HepG2 Cells in vivo: Wild Type and Hemophilia A mouse models in vivo: Non-Human Primates (NHPs) Summary and Next Steps 36
37 I N V I V O : N O N - H U M A N P R I M AT E D ATA E X P E R I M E N TA L D E S I G N AAV2 ITR Liver-specific promoter module hfviii BDD PolyA AAV2 ITR Optimized raav hf8 cdna cassette packaged into AAV2/6 IV injection of test article Doses 2.0E+12 vg/kg 6.0E+12 vg/kg days 247 days Plasma collection schedule Endpoints ELISA for hfviii levels Clotting for hfviii activity Bethesda Units (BU) for inhibitory hfviii antibodies Liver enzymes Immunosuppression regimen of Rituxan and Solu-Medrol (10 mg/kg for both) 37
38 I N V I V O : N O N - H U M A N P R I M AT E D ATA S U P R A P H Y S I O L O G I C A L L E V E L S h F V III (P e r c e n t N o rm a l) hfviii Levels % % Dose selection was based on published studies Follow up dose-finding studies are aimed at determining the minimal effective dose for the clinic E E T o ta l D o s e (v g /k g ) Levels were determined by ELISA 38
39 I N V I V O : N O N - H U M A N P R I M AT E D ATA G O O D C O R R E L AT I O N B E T W E E N A C T I V I T Y / L E V E L S h F V III (P e r c e n t N o rm a l) A c tiv ity E L IS A L e v e ls F o rm u la tio n A n im a l ID E v g /k g G ro u p Shown in the Formulation Group: Detection of ~100 % Normal NHP FVIII activity No detection of NHP FVIII levels given the ELISA is specific for human FVIII 39
40 h F V III (P e r c e n t N o rm a l) B U /m L h F V III (P e r c e n t N o rm a l) B U /m L I N V I V O : N O N - H U M A N P R I M AT E D ATA D U R A B I L I T Y A n tig e n L e v e ls A n tig e n L e v e ls B e th e s d a U n its (B U ) S o lu - M e d ro l R e m o v e d B e th e s d a U n its (B U ) S o lu - M e d ro l R e m o v e d D a y s P o s t D o s in g D a y s P o s t D o s in g Stable hfviii levels for over 8-weeks in the absence of all immunosuppression Levels were determined by ELISA 40
41 I N V I V O : N H P I M M U N E T O L E R A N C E C H A L L E N G E D U R A B I L I T Y A simplified view of tolerance is induction of B-cell/T-cell anergy and/or apoptosis in the presence of sustained levels of agent (hfviii) Do the sustained hfviii levels produced from the raav-hf8 prevent re-induction of neutralizing antibodies? raav-hf8 treated NHP were challenged with hfviii biologic hfviii biologic challenge consisted of 4 weekly infusions of 25 U/kg of Xyntha 41
42 I N V I V O : N H P I M M U N E T O L E R A N C E C H A L L E N G E N O A P P E A R A N C E O F I N H I B I T O R Y A N T I B O D I E S h F V III (P e r c e n t N o rm a l) B U /m L h F V III (P e r c e n t N o rm a l) B U /m L X y n t h a C h a l e n g e h F V III (P e r c e n t N o rm a l) P o s itiv e fo r In h ib ito ry A n tib o d ie s B U /m L Control Group AAV hf8 cdna Dose Groups A n tig e n L e v e ls B e th e s d a U n its (B U ) D a y s P o s t D o s in g X y n t h a C h a l e n g e X y n t h a C h a l l e n g e N o E v id e n c e o f In h ib ito ry A n tib o d ie s N o E v id e n c e o f In h ib ito ry A n tib o d ie s Regions shaded gray are above the BU cutpoint thus positive for inhibitory antibodies A n tig e n L e v e ls A n tig e n L e v e ls B e th e s d a U n its (B U ) D a y s P o s t D o s in g B e th e s d a U n its (B U ) D a y s P o s t D o s in g hfviii levels ~150% hfviii levels ~10% 42
43 L iv e r E n z y m e (U /L ) h F V III (P e r c e n t N o rm a l) L iv e r E n z y m e s (U /L ) h F V III (P e r c e n t N o rm a l) I N V I V O : N O N - H U M A N P R I M AT E D ATA W E L L TO L E R AT E D Control Group High Dose Group A S T A S T A L T A L T * upper limit of normal * upper limit of normal D a y s P o s t D o s in g D a y s P o s t D o s in g Elevated levels observed post-liver biopsies (day 41) * ALT = Alanine Aminotransferase, upper limit of normal,126 U/L AST = Aspartate Aminotransferase, upper limit of normal,120 U/L 43
44 L iv e r E n z y m e (U /L ) h F V III (P e r c e n t N o rm a l) L iv e r E n z y m e s (U /L ) h F V III (P e r c e n t N o rm a l) I N V I V O : N O N - H U M A N P R I M AT E D ATA W E L L TO L E R AT E D Control Group High Dose Group A S T A S T A L T h F V III L e v e ls A L T h F V III L e v e ls * upper limit of normal * upper limit of normal D a y s P o s t D o s in g D a y s P o s t D o s in g Elevated levels observed post-liver biopsies (day 41) * ALT = Alanine Aminotransferase, upper limit of normal,126 U/L AST = Aspartate Aminotransferase, upper limit of normal,120 U/L 44
45 I N V I V O : N O N - H U M A N P R I M AT E D ATA P R E L I M I N A R Y R E S U LT S D O S E - F I N D I N G S T U D Y h F V III (P e r c e n t N o rm a l) hfviii Levels Preliminary results. Dose-finding study demonstrates high hfviii production from GMP-clinical scale manufacturing process 1 6 E E E E T o ta l D o s e (v g /k g ) Levels were determined by ELISA 45
46 S U M M A RY A N D F U T U R E P L A N S Administration of AAV hf8 cdna, engineered to improve vector yields and liver-specific hfviii expression, resulted in supraphysiological levels in vivo - Wild type mice - Hemophilia A R593C mice - NHPs Good correlation between assays used to measure circulating hfviii protein - Levels by ELISA and activity by Chromogenic or Clotting assays Sustained hfviii levels from the raav-hf8 prevented re-induction of neutralizing antibodies with biologic challenge suggestive of induced tolerance (even in the context of a xenogeneic setting) Ongoing studies are aimed at determining the minimal effective dose Goal of filling the IND, second half of
47 A C K N O W L E D G E M E N T S Judy Greengard Lisa King Eudean Garces Stephen Ballaron Daniel Richards Melanie Butler Carolyn Gasper Kathy Meyer Dale Ando Richard Surosky Alicia Goodwin Andrea Kang Tim Gabriele Hung Tran Jennifer Huang David Lillicrap Christine Hough Dominique Cartier Kate Nesbitt Courtney Dwyer Kassandra Herbert Mike Holmes Jeff Boonsripisal Derek Liu Rainier Amora Lei Zhang 47
48
Investor and Analyst Breakfast
Investor and Analyst Breakfast American Society for Gene & Cell Therapy Annual Meeting Washington, D.C. May 12, 2017 This presentation contains forward-looking statements. All statements other than statements
More informationThis presentation contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform
This presentation contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements
More informationJefferies Gene Editing/Therapy Summit Matthew Kapusta, Interim Chief Executive Officer OCTOBER 11, 2016
Jefferies Gene Editing/Therapy Summit Matthew Kapusta, Interim Chief Executive Officer OCTOBER 11, 2016 This presentation contains forward-looking statements. All statements other than statements of historical
More informationSupplementary Figure 1: To test the role of mir-17~92 in orthologous genetic model of ADPKD, we generated Ksp/Cre;Pkd1 F/F (Pkd1-KO) and Ksp/Cre;Pkd1
Supplementary Figure 1: To test the role of mir-17~92 in orthologous genetic model of ADPKD, we generated Ksp/Cre;Pkd1 F/F (Pkd1-KO) and Ksp/Cre;Pkd1 F/F ;mir-17~92 F/F (Pkd1-miR-17~92KO) mice. (A) Q-PCR
More informationA Phase 1/2 Clinical Trial of Intra- Arterial Gene Transfer of raavrh74.mck.galgt2 for DMD: Initial Safety Profile
A Phase 1/2 Clinical Trial of Intra- Arterial Gene Transfer of raavrh74.mck.galgt2 for DMD: Initial Safety Profile Kevin Flanigan, MD Center for Gene Therapy Nationwide Children s Hospital June 29, 2018
More informationThe Bcl3 Story : Collabora2ve Drug Discovery In Ac2on
The Bcl3 Story : Collabora2ve Drug Discovery In Ac2on Dr Andrew Westwell Drug Development & Model Systems Package Lead Dr Luke Piggo> Research Associate, WCRC Rachel Savery Trials Project Manager (Early
More informationCorporate Presentation March 2018
Corporate Presentation March 2018 This presentation contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated
More informationInfluence of Bacterial Growth Rate on Dose Optimization of Linezolid for Treatment of Tuberculosis
Influence of Bacterial Growth Rate on Dose Optimization of Linezolid for Treatment of Tuberculosis Kristina Bigelow Johns Hopkins University School of Medicine 1/15/217 Linezolid Recently added to WHOs
More informationValidation of the GastroPlus TM Software Tool and Applications
Validation of the GastroPlus TM Software Tool and Applications Fagen Zhang and Leah Luna The Dow Chemical Company FZ/MB 01.11.11 Acknowledgements Michael Bartels Barun Bhhatarai (Novartis) Tyler Auernhammer
More informationActivation of STING with Synthetic Cyclic Dinucleotides and Synergy with Checkpoint Inhibition
Activation of STING with Synthetic Cyclic Dinucleotides and Synergy with Checkpoint Inhibition Sarah McWhirter, PhD Director, STING Program Aduro Biotech ICI Boston 2017 Presentation 1 Disclosures Sarah
More informationAlita Miller, PhD. Head of BioScience. April 24, 2017 ECCMID 2017 Vienna, Austria
ETX5 restoration of sulbactam activity against multidrug resistant Acinetobacter baumannii correlates with β-lactamase inhibition in vitro and in vivo Alita Miller, PhD Head of BioScience April, 07 ECCMID
More informationA homo-dimer of annexin V protects against ischemia reperfusion injury in lung transplantation
A homo-dimer of annexin V protects against ischemia reperfusion injury in lung transplantation K Hashimoto, H Kim, H Oishi, M Chen, I Iskender, J Sakamoto, A Ohsumi, Z Guan, DM Hwang, TK Waddell, M Cypel,
More informationSupplementary Figure 1
Supplementary Figure 1 Supplementary Figure 1. NAD + -related genes expression in mouse tissues and in cells overexpressing NRK1. mrna (a) and protein (b) levels of NRK1, NRK2 and other enzymes involved
More informationInternal dose assessment of 177 Lu-DOTA-SP for quantification of arginine renal protection effect
Internal dose assessment of 177 Lu-DOTA-SP for quantification of arginine renal protection effect 1 Puerta N., 1 Rojo A., 2 Crudo J., 2 Zapata A., 2 Nevares N., 2 López Bularte A., 2 Perez J., 2 Zaretzky
More informationB L U E V A L L E Y D I S T R I C T C U R R I C U L U M Science Anatomy & Physiology
B L U E V A L L E Y D I S T R I C T C U R R I C U L U M Science Anatomy & Physiology UNIT 1: FUNDAMENTALS (optional) Body cavities and planes, Cancer, Cells, Directional and regional terms,, Life processes,
More informationHuman Aspartate aminotransferase, AST ELISA Kit
Human Aspartate aminotransferase, AST ELISA Kit Catalog No: E1214h 96 Tests Operating instruction www.eiaab.com FOR RESEARCH USE ONLY; NOT FOR THERAPEUTIC OR DIAGNOSTIC APPLICATIONS! PLEASE READ THROUGH
More informationSUPPLEMENTARY INFORMATION
doi:10.1038/nature11419 Supplementary Figure 1 Schematic representation of innate immune signaling pathways induced by intracellular Salmonella in cultured macrophages. a, During the infection Salmonella
More information(Lys), resulting in translation of a polypeptide without the Lys amino acid. resulting in translation of a polypeptide without the Lys amino acid.
1. A change that makes a polypeptide defective has been discovered in its amino acid sequence. The normal and defective amino acid sequences are shown below. Researchers are attempting to reproduce the
More informationMultiple Choice Review- Eukaryotic Gene Expression
Multiple Choice Review- Eukaryotic Gene Expression 1. Which of the following is the Central Dogma of cell biology? a. DNA Nucleic Acid Protein Amino Acid b. Prokaryote Bacteria - Eukaryote c. Atom Molecule
More informationBACTERIAL PHYSIOLOGY SMALL GROUP. Monday, August 25, :00pm. Faculty: Adam Driks, Ph.D. Alan Wolfe, Ph.D.
BACTERIAL PHYSIOLOGY SMALL GROUP Monday, August 25, 2014 1:00pm Faculty: Adam Driks, Ph.D. Alan Wolfe, Ph.D. Learning Goal To understand how bacterial physiology applies to the diagnosis and treatment
More informationPeptides as Radiopharmaceuticals: CMC Perspectives
s as Radiopharmaceuticals: CMC Perspectives Ravindra K. Kasliwal, Ph.D. Office of New Drug Products (ONDP) Office of Pharmaceutical Quality (OPQ) Center for Drug Evaluation and Research (CDER) Food and
More informationDelivery. Delivery Processes. Delivery Processes: Distribution. Ultimate Toxicant
Delivery Ultimate Toxicant The chemical species that reacts with the endogenous target. Toxicity depends on the concentration (dose) of the ultimate toxicant at the target site Delivery Processes Absorption
More informationrobustness: revisting the significance of mirna-mediated regulation
: revisting the significance of mirna-mediated regulation Hervé Seitz IGH (CNRS), Montpellier, France October 13, 2012 microrna target identification .. microrna target identification mir: target: 2 7
More informationOrganization of Genes Differs in Prokaryotic and Eukaryotic DNA Chapter 10 p
Organization of Genes Differs in Prokaryotic and Eukaryotic DNA Chapter 10 p.110-114 Arrangement of information in DNA----- requirements for RNA Common arrangement of protein-coding genes in prokaryotes=
More informationAssessment of toxicological properties and establishment of risk profiles - genotoxic properties of selected spice compounds
Assessment of toxicological properties and establishment of risk profiles - genotoxic properties of selected spice compounds Frankfurt/Main, September 25 th 212 V.J. Koller 1, V. Auwärter 2, G. Zlabinger
More informationRegulation and signaling. Overview. Control of gene expression. Cells need to regulate the amounts of different proteins they express, depending on
Regulation and signaling Overview Cells need to regulate the amounts of different proteins they express, depending on cell development (skin vs liver cell) cell stage environmental conditions (food, temperature,
More informationSrdan Verstovsek, MD, PhD Professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center
Efficacy and Safety of Pegylated Interferon Alpha- 2a in Patients with Essential Thrombocythemia (ET) and Polycythemia vera (PV): Results after a Median 7-year Follow-up of a Phase 2 Study Srdan Verstovsek,
More informationInhibition of the AAA-ATPase p97 with the first in class inhibitor CB-5083 as a novel approach to treat cancer
Inhibition of the AAA-ATPase p97 with the first in class inhibitor CB-5083 as a novel approach to treat cancer Daniel Anderson, PhD Cleave Biosciences 1 Disclosure Information: AACR Annual meeting 2015
More informationTi plasmid derived plant vector systems: binary and co - integrative vectors transformation process; regeneration of the transformed lines
Ti plasmid derived plant vector systems: binary and co - integrative vectors transformation process; regeneration of the transformed lines Mitesh Shrestha Constraints of Wild type Ti/Ri-plasmid Very large
More informationgender mains treaming in Polis h practice
gender mains treaming in Polis h practice B E R L IN, 1 9-2 1 T H A P R IL, 2 O O 7 Gender mains treaming at national level Parliament 25 % of women in S ejm (Lower Chamber) 16 % of women in S enat (Upper
More informationClass Diagrams. CSC 440/540: Software Engineering Slide #1
Class Diagrams CSC 440/540: Software Engineering Slide # Topics. Design class diagrams (DCDs) 2. DCD development process 3. Associations and Attributes 4. Dependencies 5. Composition and Constraints 6.
More informationRANK. Alternative names. Discovery. Structure. William J. Boyle* SUMMARY BACKGROUND
RANK William J. Boyle* Department of Cell Biology, Amgen, Inc., One Amgen Center Drive, Thousand Oaks, CA 91320-1799, USA * corresponding author tel: 805-447-4304, fax: 805-447-1982, e-mail: bboyle@amgen.com
More informationTranslation Part 2 of Protein Synthesis
Translation Part 2 of Protein Synthesis IN: How is transcription like making a jello mold? (be specific) What process does this diagram represent? A. Mutation B. Replication C.Transcription D.Translation
More informationRibosome readthrough
Ribosome readthrough Starting from the base PROTEIN SYNTHESIS Eukaryotic translation can be divided into four stages: Initiation, Elongation, Termination and Recycling During translation, the ribosome
More informationSupplementary Material (ESI) for Natural Product Reports This journal is The Royal Society of Chemistry Effect on promastigotes, amastigotes of
upplementary Material (EI) for atural Product Reports This journal is The Royal ociety of Chemistry 2010 Table 2. Biological activities of purely synthetic guanidines Entry Guanidine compound Biological
More informationLOS AMMOS SCIENTIFIC LABORATORY
INKI-AWFIEJI LOS AMMOS SCIENTIFIC LABORATORY OF THE UNIVERSITY OF CALIFORNIA LOS ALAMOS, NEW MEXICO CONTRACTW-7405-ENG36 WITH THE US ATOMIC ENERGY COMMISSION IJNCA5SIHED LOS ALAMOS SCIENTIFIC LABORATORY
More informationCellular Neuroanatomy I The Prototypical Neuron: Soma. Reading: BCP Chapter 2
Cellular Neuroanatomy I The Prototypical Neuron: Soma Reading: BCP Chapter 2 Functional Unit of the Nervous System The functional unit of the nervous system is the neuron. Neurons are cells specialized
More informationLipid transfer proteins confer resistance to trichothecenes
Lipid transfer proteins confer resistance to trichothecenes John McLaughlin and Anwar Bin-Umer Tumer Laboratory National Fusarium Head Blight Forum December 6th, 2012 FY09-11: Identify trichothecene resistance
More informationc. What is the average rate of change of f on the interval [, ]? Answer: d. What is a local minimum value of f? Answer: 5 e. On what interval(s) is f
Essential Skills Chapter f ( x + h) f ( x ). Simplifying the difference quotient Section. h f ( x + h) f ( x ) Example: For f ( x) = 4x 4 x, find and simplify completely. h Answer: 4 8x 4 h. Finding the
More informationSite-Specific Prodrug Release Using Visible Light
Site-Specific Prodrug Release Using Visible Light Michael Y. Jiang and David Dolphin* J. Am. Chem. Soc., 2008, 130, 4236-4237 Li Zhang Current literature presentation 04-26-2008 Li Zhang @ Wipf Group Page
More informationPhoto. EPRI s Power System and Railroad Electromagnetic Compatibility Handbook
Photo EPRI s Power System and Railroad Electromagnetic Compatibility Handbook Brian Cramer Project Manager Transmission and Substations bcramer@epri.com 815/478-5344 Problem Periodic false activation of
More informationProteomics. Areas of Interest
Introduction to BioMEMS & Medical Microdevices Proteomics and Protein Microarrays Companion lecture to the textbook: Fundamentals of BioMEMS and Medical Microdevices, by Prof., http://saliterman.umn.edu/
More informationPassaic County Technical Institute. Wayne, NJ. Anatomy and Physiology II Curriculum. August 2015
Passaic County Technical Institute Wayne, NJ Anatomy and Physiology II Curriculum August 2015 Anatomy and Physiology II Curriculum August 2015 I. Course Description Anatomy and Physiology II is a full
More informationGCD3033:Cell Biology. Transcription
Transcription Transcription: DNA to RNA A) production of complementary strand of DNA B) RNA types C) transcription start/stop signals D) Initiation of eukaryotic gene expression E) transcription factors
More information1. In most cases, genes code for and it is that
Name Chapter 10 Reading Guide From DNA to Protein: Gene Expression Concept 10.1 Genetics Shows That Genes Code for Proteins 1. In most cases, genes code for and it is that determine. 2. Describe what Garrod
More informationCHAPTER 1 THE STRUCTURAL BIOLOGY OF THE FGF19 SUBFAMILY
CHAPTER 1 THE STRUCTURAL BIOLOGY OF THE FGF19 SUBFAMILY Andrew Beenken and Moosa Mohammadi* Department of Pharmacology, New York University School of Medicine, New York, New York, USA. *Corresponding Author:
More informationCardiolipin Remodeling by ALCAT1 Regulates Dilated Cardiomyopathy Through Oxidative Stress and Mitophagy. Yuguang (Roger) Shi
Cardiolipin Remodeling by ALCAT1 Regulates Dilated Cardiomyopathy Through xidative Stress and Mitophagy Yuguang (Roger) Shi yus11@psu.eud Cardiolipin Biosynthetic and Remodeling Pathways Phosphatidic Acid
More informationTopic 1 - The building blocks of. cells! Name:!
B2 - Revision Topic 1 - The building blocks of Lesson cells Name: Topic B2.1 Plant and Animal Cells B2.2 Inside Bacteria B2.3 DNA B2.4 Extracting DNA: PCA B2.5 DNA Discovery B2.6 Genetic Engineering B2.7
More informationTechnology Platform 2018
Technology Platform 2018 Forward Looking Statements This presentation contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform
More informationThe Longer Life Foundation Pilot/Feasibility Grant Application FINAL REPORT
The Longer Life Foundation Pilot/Feasibility Grant Application FINAL REPORT Diagnostic and therapeutic applications of a novel plasma metabolite, nicotinamide mononucleotide (NMN), for age-associated metabolic
More informationFSC-W FSC-H CD4 CD62-L
Supplementary Fig. 1 a SSC-A FSC-A FSC-W FSC-H SSC-W SSC-H CD4 CD62-L b SSC-A FSC-A FSC-W FSC-A FSC-A 7-AAD FSC-A CD4 IL-9 CD4 c SSC-A FSC-A FSC-W FSC-H SSC-W SSC-H 7-AAD KI67 Annexin-V 7-AAD d I L -5
More informationScope & Outline. Joanna A. Korecka
Scope & Outline Joanna A. Korecka 10 Scope Parkinson s disease (PD) is a progressive neurodegenerative disorder. According to the Parkinson s Disease Foundation, 7 to 10 million people suffer from PD worldwide.
More informationPET Tracer Kinetic Modeling In Drug
PET Tracer Kinetic Modeling In Drug Discovery Research Applications Sandra M. Sanabria-Bohórquez Imaging Merck & Co., Inc. Positron Emission Tomography - PET PET is an advanced d imaging i technique permitting
More informationOCR Biology Checklist
Topic 1. Cell level systems Video: Eukaryotic and prokaryotic cells Compare the structure of animal and plant cells. Label typical and atypical prokaryotic cells. Compare prokaryotic and eukaryotic cells.
More informationOCR Biology Checklist
Topic 1. Cell level systems Video: Eukaryotic and prokaryotic cells Compare the structure of animal and plant cells. Label typical and atypical prokaryotic cells. Compare prokaryotic and eukaryotic cells.
More informationForm and content. Iowa Research Online. University of Iowa. Ann A Rahim Khan University of Iowa. Theses and Dissertations
University of Iowa Iowa Research Online Theses and Dissertations 1979 Form and content Ann A Rahim Khan University of Iowa Posted with permission of the author. This thesis is available at Iowa Research
More informationGene Control Mechanisms at Transcription and Translation Levels
Gene Control Mechanisms at Transcription and Translation Levels Dr. M. Vijayalakshmi School of Chemical and Biotechnology SASTRA University Joint Initiative of IITs and IISc Funded by MHRD Page 1 of 9
More informationPART II VIII. CONCERNING CHEMICAL. PHARMACEUTICAL AND BIOLOGICAL DOCUMENTATION FOR RADIOPHARMACEUTICAL PRODUCTS.
PART II VIII. CONCERNING CHEMICAL. PHARMACEUTICAL AND BIOLOGICAL DOCUMENTATION FOR RADIOPHARMACEUTICAL PRODUCTS. The principle of GMP and the detailed guidelines are applicable to all operations which
More informationNuclear Physics and Astrophysics
Nuclear Physics and Astrophysics PHY-302 Dr. E. Rizvi Lecture 24 Medical Imaging Effects of Radiation We now know what radiation is But what does it mean for our bodies? Radioactivity is quantified in
More informationPathogen Inactivation and Function of Platelets and Red Cells
Pathogen Inactivation and Function of Platelets and Red Cells Dr. Dana Devine Professor of Pathology & Laboratory Medicine UBC Centre for Blood Research Chief Medical and Scientific Officer, Canadian Blood
More informationMEDLINE Clinical Laboratory Sciences Journals
Source Type Publication Name ISSN Peer-Reviewed Academic Journal Acta Biochimica et Biophysica Sinica 1672-9145 Y Academic Journal Acta Physiologica 1748-1708 Y Academic Journal Aging Cell 1474-9718 Y
More informationDifferent Biodegradable Silica Structures In Drug Delivery. Mika Jokinen
Different Biodegradable Silica Structures In Drug Delivery Mika Jokinen & Different Morphologies of Biodegradable Silica - Several levels of morphology ; different forms & structures - monoliths, fibers,
More informationArea of Focus: Biology. Learning Objective 1: Describe the structure and function of organs. Pre-Learning Evaluation: Teaching Methods and Process:
Area of Focus: Biology Learning Objective 1: Describe the structure and function of organs. Pre- Diagram and label the structure of the primary components of representative organs in plants and animals
More informationProkaryotic Regulation
Prokaryotic Regulation Control of transcription initiation can be: Positive control increases transcription when activators bind DNA Negative control reduces transcription when repressors bind to DNA regulatory
More informationLung-residing myeloid-derived suppressors display dual functionality in murine. pulmonary tuberculosis
Lung-residing myeloid-derived suppressors display dual functionality in murine pulmonary tuberculosis Julia K. Knaul, Sabine Jörg, Dagmar Oberbeck-Mueller, Ellen Heinemann, Lisa Scheuermann, Volker Brinkmann,
More informationOrganelles & Cells Student Edition. A. chromosome B. gene C. mitochondrion D. vacuole
Name: Date: 1. Which structure is outside the nucleus of a cell and contains DNA? A. chromosome B. gene C. mitochondrion D. vacuole 2. A potato core was placed in a beaker of water as shown in the figure
More informationChapters 12&13 Notes: DNA, RNA & Protein Synthesis
Chapters 12&13 Notes: DNA, RNA & Protein Synthesis Name Period Words to Know: nucleotides, DNA, complementary base pairing, replication, genes, proteins, mrna, rrna, trna, transcription, translation, codon,
More informationLooking Back to Move Forward - Designing Next Gen RNAi for HBV. HepDart December 5, 2017
Looking Back to Move Forward - Designing Next Gen RNAi for HBV HepDart December 5, 2017 Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the "safe harbor"
More informationIntroduction to Molecular and Cell Biology
Introduction to Molecular and Cell Biology Molecular biology seeks to understand the physical and chemical basis of life. and helps us answer the following? What is the molecular basis of disease? What
More informationFRAUNHOFER IME SCREENINGPORT
FRAUNHOFER IME SCREENINGPORT Design of screening projects General remarks Introduction Screening is done to identify new chemical substances against molecular mechanisms of a disease It is a question of
More informationand their organelles
and their organelles Discovery Video: Cells REVIEW!!!! The Cell Theory 1. Every living organism is made of one or more cells. 2. The cell is the basic unit of structure and function. It is the smallest
More informationBases of radioisotope diagnostic methods
Medical, pharmaceutical applications of radioisotopes Bases of radioisotope diagnostic methods Dr. István Voszka Basis of application: radioisotopes have identical behavior in the organism to corresponding
More informationPrealbumin (Mouse) ELISA KitI
Prealbumin (Mouse) ELISA KitI Catalog Number KA2070 96 assays Version: 04 Intended for research use only www.abnova.com Table of Contents Introduction... 3 Intended Use... 3 Background... 3 Principle of
More informationPrinciples of Drug Design
Advanced Medicinal Chemistry II Principles of Drug Design Tentative Course Outline Instructors: Longqin Hu and John Kerrigan Direct questions and enquiries to the Course Coordinator: Longqin Hu I. Introduction
More informationmicrorna pseudo-targets
microrna pseudo-targets Natalia Pinzón Restrepo Institut de Génétique Humaine (CNRS), Montpellier, France August, 2012 microrna target identification mir: target: 2 7 5 N NNNNNNNNNNNNNN NNNNNN 3 the seed
More informationMOLECULAR BIOLOGY BIOL 021 SEMESTER 2 (2015) COURSE OUTLINE
COURSE OUTLINE 1 COURSE GENERAL INFORMATION 1 Course Title & Course Code Molecular Biology: 2 Credit (Contact hour) 3 (2+1+0) 3 Title(s) of program(s) within which the subject is taught. Preparatory Program
More informationProcess Development & Scale-Up of the AIR Technology
Process Development & Scale-Up of the AIR Technology Lloyd Johnston, Ph.D. Vice President of Process Development & Manufacturing October 6, 2005 Pharmaceutical Industry o Delivering needed therapeutics
More information2012 Univ Aguilera Lecture. Introduction to Molecular and Cell Biology
2012 Univ. 1301 Aguilera Lecture Introduction to Molecular and Cell Biology Molecular biology seeks to understand the physical and chemical basis of life. and helps us answer the following? What is the
More informationMidterm Review Guide. Unit 1 : Biochemistry: 1. Give the ph values for an acid and a base. 2. What do buffers do? 3. Define monomer and polymer.
Midterm Review Guide Name: Unit 1 : Biochemistry: 1. Give the ph values for an acid and a base. 2. What do buffers do? 3. Define monomer and polymer. 4. Fill in the Organic Compounds chart : Elements Monomer
More informationDepartment Curriculum and Assessment Outline
Department: Science Year Group: 10 Teaching, learning and assessment during the course: Combined Science 1 2 B1 Key concepts in Biology B2 Cells and control What are the structure and function of cells.
More informationChapter 17. From Gene to Protein. Biology Kevin Dees
Chapter 17 From Gene to Protein DNA The information molecule Sequences of bases is a code DNA organized in to chromosomes Chromosomes are organized into genes What do the genes actually say??? Reflecting
More informationWhat is the central dogma of biology?
Bellringer What is the central dogma of biology? A. RNA DNA Protein B. DNA Protein Gene C. DNA Gene RNA D. DNA RNA Protein Review of DNA processes Replication (7.1) Transcription(7.2) Translation(7.3)
More informationBiology EOC Review Study Questions
Biology EOC Review Study Questions Microscopes and Characteristics of Life 1. How do you calculate total magnification on a compound light microscope? 2. What is the basic building block of all living
More informationWhich row in the chart correctly identifies the functions of structures A, B, and C? A) 1 B) 2 C) 3 D) 4
1. What is a similarity between all bacteria and plants? A) They both have a nucleus B) They are both composed of cells C) They both have chloroplasts D) They both lack a cell wall 2. Which statement is
More informationCHAPTER 3. Cell Structure and Genetic Control. Chapter 3 Outline
CHAPTER 3 Cell Structure and Genetic Control Chapter 3 Outline Plasma Membrane Cytoplasm and Its Organelles Cell Nucleus and Gene Expression Protein Synthesis and Secretion DNA Synthesis and Cell Division
More informationCharacterizing degradation kinetics and cellular mechanisms of PROTAC compounds. Kristin M. Riching, Ph.D. Protein Degradation Therapeutics 2018
Characterizing degradation kinetics and cellular mechanisms of PROTAC compounds Kristin M. Riching, Ph.D. Protein Degradation Therapeutics 28 Understanding the Dynamics and Mechanisms of Protein Degradation
More informationNa Li, PhD. Application of a Fluorescent Substrate / Inside-Out Transporter Vesicle Assay for Identifying Inhibitors of MRP Transport
Application of a Fluorescent Substrate / Inside-Out Transporter Vesicle Assay for Identifying Inhibitors of MRP Transport Na Li, PhD BD Biosciences October 20, 2010 BD Gentest Transporter Seminar Series
More informationFlow of Genetic Information
presents Flow of Genetic Information A Montagud E Navarro P Fernández de Córdoba JF Urchueguía Elements Nucleic acid DNA RNA building block structure & organization genome building block types Amino acid
More informationThe performance expectation above was developed using the following elements from A Framework for K-12 Science Education:
HS-LS1-1 HS-LS1-1. Construct an explanation based on evidence for how the structure of DNA determines the structure of proteins which carry out the essential functions of life through systems of specialized
More informationBET PROTACs Are More Broadly Effective Than BET Inhibitors. Dr. Kevin Coleman Arvinas, LLC New Haven, CT
BET PROTACs Are More Broadly Effective Than BET Inhibitors Dr. Kevin Coleman Arvinas, LLC New Haven, CT 1 Disclosures I am an employee of and have an equity stake in Arvinas 2 Arvinas: The Protein Degradation
More informationWhat Organelle Makes Proteins According To The Instructions Given By Dna
What Organelle Makes Proteins According To The Instructions Given By Dna This is because it contains the information needed to make proteins. assemble enzymes and other proteins according to the directions
More informationIn my opinion this paper can become suitable for publication, provided below issues are adequately addressed.
Reviewers' comments: Reviewer #1 (Remarks to the Author): Wagner and colleagues describe an appealing approach to modulate the properties of a drug, this case warfarin, by means of click chemistry in vivo.
More informationBig Idea 3: Living systems store, retrieve, transmit and respond to information essential to life processes. Tuesday, December 27, 16
Big Idea 3: Living systems store, retrieve, transmit and respond to information essential to life processes. Enduring understanding 3.B: Expression of genetic information involves cellular and molecular
More informationName: TF: Section Time: LS1a ICE 5. Practice ICE Version B
Name: TF: Section Time: LS1a ICE 5 Practice ICE Version B 1. (8 points) In addition to ion channels, certain small molecules can modulate membrane potential. a. (4 points) DNP ( 2,4-dinitrophenol ), as
More informationChapter 1. DNA is made from the building blocks adenine, guanine, cytosine, and. Answer: d
Chapter 1 1. Matching Questions DNA is made from the building blocks adenine, guanine, cytosine, and. Answer: d 2. Matching Questions : Unbranched polymer that, when folded into its three-dimensional shape,
More informationNonlinear pharmacokinetics
5 Nonlinear pharmacokinetics 5 Introduction 33 5 Capacity-limited metabolism 35 53 Estimation of Michaelis Menten parameters(v max andk m ) 37 55 Time to reach a given fraction of steady state 56 Example:
More informationMouse Anti-OVA-IgE ELISA KIT
Mouse Anti-OVA-IgE ELISA KIT Research Reagent Please, read this instruction carefully before use. This is an ELISA (Enzyme Linked ImmunoSorbent Assay) kit for measurement of mouse anti-ova (ovalbumin)-ige
More informationCHEM 121: Chemical Biology
Instructors Prof. Jane M. Liu (HS-212) jliu3@drew.edu x3303 Office Hours Anytime my office door is open CHEM 121: Chemical Biology Class MF 2:30-3:45 pm PRE-REQUISITES: CHEM 117 COURSE OVERVIEW This upper-level
More information1 GO: regulation of cell size E-04 2 GO: negative regulation of cell growth GO:
Table S2: The biological modulated by mir-5701 Sr. No Term Id 1 Term Name 2 Hit Gene Number 3 P-Value 4 1 GO:0008361 regulation of cell size 9 4.37E-04 2 GO:0030308 negative regulation of cell growth 8
More informationSupplementary Tables and Figures
Supplementary Tables Supplementary Tables and Figures Supplementary Table 1: Tumor types and samples analyzed. Supplementary Table 2: Genes analyzed here. Supplementary Table 3: Statistically significant
More information